Avalon GloboCare Strengthens Position with New CAR-T Patent
Avalon GloboCare Strengthens Its Intellectual Property Portfolio
Avalon GloboCare Corp. (NASDAQ: ALBT), a pioneering developer focused on precision diagnostic consumer products, has recently made significant strides by securing a new patent for its cutting-edge CAR-T and CAR-NK cell technology. This milestone was officially recognized by the Hong Kong Intellectual Property Department, marking a noteworthy addition to Avalon’s global intellectual property arsenal.
A Major Step in Cell Therapy Innovation
This new patent, based on a previously granted Chinese patent (ZL202080015205.0), has been designated as Patent No. HK40074322. Effective as of February 21, 2020, this 20-year patent guarantees Avalon long-lasting protection and exclusivity for its innovative CAR-T and CAR-NK cell technologies within the region. The patent is pivotal to Avalon’s strategic business plan and global intellectual property strategy.
Collaboration with Strategic Partners
The cutting-edge CAR-T technology was co-developed with Arbele Limited, a strategic partner based in Hong Kong. This collaboration not only enhances Avalon’s capabilities in chimeric antigen receptor (CAR)-based therapies but also serves to solidify its existing patent protections across multiple jurisdictions, including the United States and other territories under the Patent Cooperation Treaty (PCT).
Innovative Features of the Patented Technology
Avalon's patented technology includes features designed to respond to common challenges faced by existing therapies:
1. Bispecific Anti-CD19xCD22 CAR Design: This innovative design targets both CD19 and CD22 antigens, effectively reducing risks related to tumor escape due to antigen loss, a prevalent issue in hematologic malignancies.
2. Localized Cytokine Induction: This method intends to activate immune responses at specific tumor sites, promoting improved proliferation, cytotoxicity, and overall persistence of CAR cells, thereby stimulating the patient's immune system.
Future Implications and Company Outlook
According to David Jin, M.D., Ph.D., and CEO of Avalon GloboCare, this patent is more than just a legal protection—it's a fundamental expansion of Avalon’s intellectual property portfolio. It reinforces the company’s competitive position in the evolving and expanding field of cell-based immunotherapy. He noted, "With 20 years of patent protection assured in Hong Kong, this represents a strategic stride toward strengthening our intellectual property portfolio."
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in creating precision diagnostic consumer products while advancing intellectual property in cellular therapy. Currently, the company markets the KetoAir™ breathalyzer device, manufactured by Qi Diagnostics Limited. The breathalyzer is recognized as a Class I medical device by the U.S. Food and Drug Administration and is set to be developed for additional diagnostic applications. Beyond these innovative products, Avalon is committed to expanding its intellectual property holdings through ongoing patent applications, while also owning and operating commercial real estate to support its operational growth.
Contact Information
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
Email: PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
Email: albt@crescendo-ir.com
Frequently Asked Questions
What is the newly issued patent for Avalon GloboCare?
The newly issued patent pertains to Avalon GloboCare's proprietary CAR-T and CAR-NK cell technology, enhancing their position in cell-based immunotherapy.
How long is the patent protection valid?
The patent protection is valid for 20 years, effective from February 21, 2020.
Who developed the CAR-T technology with Avalon GloboCare?
The CAR-T technology was co-developed with Arbele Limited, a strategic partner based in Hong Kong.
What are the unique features of the CAR-T technology?
It features a Bispecific Anti-CD19xCD22 CAR Design and Localized Cytokine Induction for improved treatment efficacy.
What other products does Avalon offer?
Avalon markets the KetoAir™ breathalyzer and plans to develop additional diagnostic applications using this technology.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.